Dentsply Sirona Q3 net sales $947M, GAAP EPS loss $5.01; FY22 adj. EPS cut to $1.90-$2.00

DENTSPLY SIRONA Inc.

2022-Q3 EPS reported -$4.34 revenue$2,939,000,000

Net sales down 8.9% to $947M; organic sales -0.7%; FX headwind of 8.2%.
GAAP net loss of $1,077M, or ($5.01) per diluted share, vs. $0.38 EPS in Q3 2021.
Adjusted EPS $0.41, down 31.5% YoY from $0.60; adjusted operating margin 14.7% vs 18.2%.
Updated FY22 outlook: organic sales decline ~2%; adj. EPS $1.90-$2.00 (previous $2.25-$2.45).
CEO cites macroeconomic headwinds; comprehensive business review initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DENTSPLY SIRONA Inc. reported the third quarter ended September 30, 2022 results: revenue $947 million, net income ($1,077) million, EPS ($5.01) loss per diluted share.

Period: the third quarter ended September 30, 2022
Revenue: $947 million
Net income: ($1,077) million
EPS: ($5.01) loss per diluted share
Result: reported results

Exact text from the filing

Charlotte, N.C., November 14, 2022 - DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its financial results for the third quarter of 2022. Third quarter net sales of $947 million decreased (8.9%), compared to $1,040 million in the third quarter of 2021. Foreign currency translation negatively impacted sales by (8.2%). Net loss for the third quarter of 2022 was ($1,077) million, or ($5.01) loss per diluted share, compared to $84 million, or $0.38 per diluted share in the third quarter of 2021.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

DENTSPLY SIRONA Inc. filing history →

Source: SEC EDGAR

accession 0000818479-22-000116

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.